RCAG
XLRN

Rehmann Capital Advisory Group’s Acceleron Pharma XLRN Stock Holding History

Rehmann Capital Advisory Group’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-14
Closed -$679 – 2205
2018
Q2 		$679 Buy
+14
New +$510 ﹤0.01% 2031

Other funds holding XLRN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Rehmann Capital Advisory Group's XLRN Position: Q3 2018 in Review

Rehmann Capital Advisory Group sold out of Acceleron Pharma (XLRN) in Q3 2018, closing a stake of 14 shares — an estimated $679 sold.

Rehmann Capital Advisory Group first reported a position in XLRN in Q2 2018 and held it in 1 quarter. The position peaked at $679 in Q2 2018. 167 funds tracked by Wall St. Rank hold XLRN as of Q3 2018.

  • Rehmann Capital Advisory Group reported no remaining Acceleron Pharma position as of Q3 2018 after selling out during the quarter.
  • Rehmann Capital Advisory Group sold 14 Acceleron Pharma shares in Q3 2018, an estimated $679.
  • Rehmann Capital Advisory Group first reported a position in Acceleron Pharma in Q2 2018 and held it in 1 quarter.
  • Rehmann Capital Advisory Group's Acceleron Pharma position peaked at $679 in Q2 2018.
  • 167 funds tracked by Wall St. Rank held Acceleron Pharma as of Q3 2018.

Based on Rehmann Capital Advisory Group's 13F filing for Q3 2018, filed 20 Nov 2018.